692 Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.